Altimmune Announced Sunday. Phase 2b IMPACT 48-Week Pemvidutide Data In MASH, Showing Significantly Higher Composite Response Rates For Liver Inflammation, Fibrosis Improvement And Disease Remission Vs. Placebo, Supporting Phase 3 Development
Share
Why It Matters
Altimmune's medicine helped people's livers get healthier in testing. This good result means they can move forward to the next bigger testing phase.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.